Option agreement with Daiichi Sankyo Co., Ltd. for the treatment of respiratory diseases including COVID-19 pneumonia and other lung injuries

January 17, 2021

January 17, 2021 – Renascience Inc. (“Renascience” headquartered at Chuo-ku, Tokyo) today announced executing an option agreement with Daiichi Sankyo Co., Ltd. (”Daiichi Sankyo” headquartered at Chuo-ku, Tokyo, Japan) for RS5614 (PAI-1 inhibitor), a compound developed by Renascience.

In the agreement, Renascience grants Daiichi Sankyo an exclusive right to negotiate with Renascience on worldwide license for the development and commercialization of RS5614 in the treatment of respiratory diseases such as the new coronavirus (COVID-19) pneumonia and other lung injuries.

Renascience continues to promote the domestic multi-center Phase II investigator-initiated clinical trials for COVID-19 pneumonia, utilizing a financial support from the Japan Agency for Medical Development (AMED) on its second open call of “Research and Development Project for Promotion of Innovative Drugs for Emerging and Re-emerging Infectious Diseases FY2020: Development of Therapeutic Drugs for New Coronavirus Infections (COVID-19)”. Renascience is also supporting Phase II investigator-initiated clinical trials for COVID-19 pneumonia that are being conducted independently in the U.S. and the Republic of Turkey in cooperation with medical institutions there.

Renascience continues utilizing its research and development capabilities to develop drugs that prevent severe deteriorations of pneumonia caused by COVID-19 and improve lung injuries. Renascience, thus, continues making further contributions to reduce the burden both on patients and the healthcare professionals in the medical institutions.

Renascience’s efforts for the development of drugs for COVID-19
Click here for more information on our COVID-19 therapeutic candidate development project.

For further inquiries
Renascience Inc.  Finance & Administration Department +81-3-6262-0873